Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INSULET CORPORATION

(PODD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insulet : Cowen Analyst Assumes Coverage on Outperform-Rated Insulet, Sets $310 Price Target

07/21/2021 | 12:50pm EDT


© MT Newswires 2021
All news about INSULET CORPORATION
08/26INSULET : to Present at Upcoming Investor Conferences
BU
08/19INSULET : Significant Insider Selling in Shares of Insulet (PODD) Continues
MT
08/19INSIDER TRENDS : Insulet Insider Exercises Options in Face of 90-Day Selling Tre..
MT
08/18INSIDER TRENDS : Insulet Insider Extends 90-Day Selling Trend
MT
08/16INSULET : Says FDA Clears Use of Its Insulin Management Products With Eli Lilly'..
MT
08/16INSULET : Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with ..
BU
08/16Insulet Corporation Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin ..
CI
08/11INSULET : Introduces Omnipod DASH® System at Australasian Diabetes Congress
BU
08/11Insulet Introduces Omnipod DASH System at Australasian Diabetes Congress
CI
08/10INSIDER TRENDS : 90-Day Insider Buying Trend Scaled Back with Sale of Insulet Sh..
MT
More news
Analyst Recommendations on INSULET CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 085 M - -
Net income 2021 21,8 M - -
Net Debt 2021 260 M - -
P/E ratio 2021 869x
Yield 2021 -
Capitalization 20 073 M 20 073 M -
EV / Sales 2021 18,7x
EV / Sales 2022 15,5x
Nbr of Employees 1 900
Free-Float 99,6%
Chart INSULET CORPORATION
Duration : Period :
Insulet Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INSULET CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 291,44 $
Average target price 285,37 $
Spread / Average Target -2,08%
EPS Revisions
Managers and Directors
Shacey Petrovic President, Chief Executive Officer & Director
Wayde Dwight McMillan Chief Financial Officer, Treasurer & Executive VP
Timothy J. Scannell Independent Chairman
Trang Ly Senior Vice President & Medical Director
Charles Alpuche Chief Operations Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INSULET CORPORATION15.12%20 073
ABBOTT LABORATORIES16.44%226 016
MEDTRONIC PLC12.39%177 176
BECTON, DICKINSON AND COMPANY4.58%75 152
HOYA CORPORATION33.15%63 447
SARTORIUS STEDIM BIOTECH82.07%57 757